BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31181961)

  • 1. Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda.
    Tram KH; Mwangwa F; Chamie G; Atukunda M; Owaraganise A; Ayieko J; Jain V; Clark TD; Kwarisiima D; Petersen ML; Kamya MR; Charlebois ED; Havlir DV; Marquez C;
    AIDS Care; 2020 Jan; 32(1):119-127. PubMed ID: 31181961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
    Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
    AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
    van Griensven J; Choun K; Chim B; Thai S; Lorent N; Lynen L
    Trop Med Int Health; 2015 Dec; 20(12):1823-31. PubMed ID: 26426387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.
    Jacobson KB; Niccolai L; Mtungwa N; Moll AP; Shenoi SV
    AIDS Care; 2017 Jul; 29(7):936-942. PubMed ID: 28147705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoniazid preventive therapy completion between July-September 2019: A comparison across HIV differentiated service delivery models in Uganda.
    Mugenyi L; Namuwenge PM; Ouma S; Bakashaba B; Nanfuka M; Zech J; Agaba C; Mijumbi Ojok A; Kaliba F; Bossa Kato J; Opito R; Miya Y; Katureebe C; Hirsch-Moverman Y
    PLoS One; 2024; 19(1):e0296239. PubMed ID: 38166009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi.
    Little KM; Khundi M; Barnes GL; Ngwira LG; Nkhoma A; Makombe S; Corbett EL; Chaisson RE; Dowdy DW
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):371-377. PubMed ID: 29562983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study.
    Dhungana GP; Thekkur P; Chinnakali P; Bhatta U; Pandey B; Zhang WH
    BMJ Open; 2019 May; 9(5):e029058. PubMed ID: 31147370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and predictors of tuberculosis among HIV patients who completed isoniazid preventive therapy (IPT) at Reach out Mbuya community health initiative.
    Sekayi W; Namyalo E; Namayanja J; Kungu JM
    Sci Rep; 2023 Oct; 13(1):17602. PubMed ID: 37845357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
    Sabasaba A; Mwambi H; Somi G; Ramadhani A; Mahande MJ
    BMC Infect Dis; 2019 Jan; 19(1):62. PubMed ID: 30654753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.
    Robert M; Todd J; Ngowi BJ; Msuya SE; Ramadhani A; Sambu V; Jerry I; Mujuni MR; Mahande MJ; Ngocho JS; Maokola W
    BMC Infect Dis; 2020 Apr; 20(1):276. PubMed ID: 32276618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.
    Hunter OF; Kyesi F; Ahluwalia AK; Daffé ZN; Munseri P; von Reyn CF; Adams LV
    BMC Infect Dis; 2020 Oct; 20(1):738. PubMed ID: 33028260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.
    Karanja M; Kingwara L; Owiti P; Kirui E; Ngari F; Kiplimo R; Maina M; Masini E; Onyango E; Ngugi C
    PLoS One; 2020; 15(12):e0234588. PubMed ID: 33264300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis.
    Geremew D; Endalamaw A; Negash M; Eshetie S; Tessema B
    BMC Infect Dis; 2019 May; 19(1):405. PubMed ID: 31077133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study.
    Semu M; Fenta TG; Medhin G; Assefa D
    BMC Infect Dis; 2017 Jan; 17(1):5. PubMed ID: 28049455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid preventive therapy use among patients on antiretroviral therapy: a missed opportunity.
    Kufa T; Chihota VN; Charalambous S; Churchyard GJ
    Int J Tuberc Lung Dis; 2014 Mar; 18(3):312-4. PubMed ID: 24670568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study.
    Kazibwe A; Oryokot B; Mugenyi L; Kagimu D; Oluka AI; Kato D; Ouma S; Tayebwakushaba E; Odoi C; Kakumba K; Opito R; Mafabi CG; Ochwo M; Nkabala R; Tusiimire W; Kateeba Tusiime A; Alinga SB; Miya Y; Etukoit MB; Biraro IA; Kirenga B
    PLoS One; 2022; 17(5):e0266285. PubMed ID: 35576223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.
    Thindwa D; MacPherson P; Choko AT; Khundi M; Sambakunsi R; Ngwira LG; Kalua T; Webb EL; Corbett EL
    Int J Tuberc Lung Dis; 2018 Mar; 22(3):273-279. PubMed ID: 29471904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
    Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
    Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
    Golub JE; Pronyk P; Mohapi L; Thsabangu N; Moshabela M; Struthers H; Gray GE; McIntyre JA; Chaisson RE; Martinson NA
    AIDS; 2009 Mar; 23(5):631-6. PubMed ID: 19525621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Isoniazid Preventive Therapy Care Cascade Among HIV-Positive Female Sex Workers in Mombasa, Kenya.
    LaCourse SM; Deya RW; Graham SM; Masese LN; Jaoko W; Mandaliya KN; Overbaugh J; McClelland RS
    J Acquir Immune Defic Syndr; 2017 Sep; 76(1):74-81. PubMed ID: 28797022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.